Clément Picard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clément Picard has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Antoine Roux
Department of Pneumology, Foch Hospital, Suresnes, France
4 shared publications - Jérôme Le Pavec
Department of Respiratory Medicine, Marie Lannelongue Hospital, Paris Saint Joseph Hospital, Le Plessis Robinson, France
4 shared publications - Natalia Belousova
Department of Pneumology, Foch Hospital, Suresnes, France
4 shared publications - Vincent Bunel
APHP Nord-Université Paris Cité, Hôpital Bichat, Service de Pneumologie B et Transplant Pulmonaire, Université Paris Cité, UMR 1149, Centre de Recherche de l'Inflammation, 75018, France
4 shared publications - Benjamin Coiffard
Department of Respiratory Medicine and Lung Transplantation Hôpital Nord Assistance Publique–Hôpitaux de Marseille (AP‐HM) Aix Marseille University Marseille France
3 shared publications - Edouard Sage
Department of Thoracic Surgery and Lung Transplantation Foch Hospital Suresnes France
3 shared publications
Latest Publications
- Open Access
- 21 August 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (1) , 37-46
Diagnostic significance of intragraft donor–specific anti-HLA antibodies in pulmonary antibody–mediated rejection
- 21 August 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (1) , 37-46
Open AccessDiagnostic significance of intragraft donor–specific anti-HLA antibodies in pulmonary antibody–mediated rejection
- 2 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , 1749-1762
Trajectories of FEV1 after lung transplantation and patient outcomes
- 2 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , 1749-1762
Trajectories of FEV1 after lung transplantation and patient outcomes
- 18 February 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1540-1546
Perioperative C1-esterase inhibitor therapy to allow transplantation in a highly sensitized lung transplant candidate: Three case reports
- 18 February 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (7) , 1540-1546
Perioperative C1-esterase inhibitor therapy to allow transplantation in a highly sensitized lung transplant candidate: Three case reports
- Open Access
- 21 June 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (10) , 1727-1736
Outcomes of lung transplantation for pleuroparenchymal fibroelastosis: A French multicentric retrospective study
- 21 June 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (10) , 1727-1736
Open AccessOutcomes of lung transplantation for pleuroparenchymal fibroelastosis: A French multicentric retrospective study
- Open Access
- 4 April 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 63 (5) , 2301809
High risk of lung cancer in surfactant-related gene variant carriers
Background: Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.Methods: We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.Results: We identified 99 SRG adult variant carriers (SFTPA1(n=18),SFTPA2(n=31),SFTPC(n=24),ABCA3(n=14) andNKX2-1(n=12)), including 20 (20.2%) with lung cancer (SFTPA1(n=7),SFTPA2(n=8),SFTPC(n=3),NKX2-1(n=2) andABCA3(n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) andSFTPA1/SFTPA2variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patientsversusTRG patients was 18.1 (95% CI 7.1–44.7).Conclusions: The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.
- 4 April 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 63 (5) , 2301809
Open AccessHigh risk of lung cancer in surfactant-related gene variant carriers
Background: Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.Methods: We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.Results: We identified 99 SRG adult variant carriers (SFTPA1(n=18),SFTPA2(n=31),SFTPC(n=24),ABCA3(n=14) andNKX2-1(n=12)), including 20 (20.2%) with lung cancer (SFTPA1(n=7),SFTPA2(n=8),SFTPC(n=3),NKX2-1(n=2) andABCA3(n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) andSFTPA1/SFTPA2variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patientsversusTRG patients was 18.1 (95% CI 7.1–44.7).Conclusions: The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.
- Open Access
- 23 August 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (1) , 89-103
Center variability in the prognostic value of a cumulative acute cellular rejection “A-score” for long-term lung transplant outcomes
- 23 August 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (1) , 89-103
Open AccessCenter variability in the prognostic value of a cumulative acute cellular rejection “A-score” for long-term lung transplant outcomes
- Open Access
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (2) , 294-297
First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report
- 12 January 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (2) , 294-297
Open AccessFirst use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report